Corona Remedies

Not Rated
  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE02ZQ01018
  • NSEID: CORONA
  • BSEID: 544644
INR
1,361.90
-42.6 (-3.03%)
BSENSE

Dec 18

BSE+NSE Vol: 5.92 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Consolidated - Profit And Loss Results
Mar'25
Mar'24
Mar'23
No of Months
12
12
12
Operating Income
1,196.00
1,014.00
884.00
Less :Inter divisional transfers
0.00
0.00
0.00
Less: Excise
0.00
0.00
0.00
Net Sales
1,196.00
1,014.00
884.00
Expenditure (Ex Depriciation)
Stock Adjustments
-23.00
0.00
-14.00
Raw Materials Consumed
260.00
227.00
225.00
Power & Fuel Cost
6.00
5.00
3.00
Employee Cost
346.00
295.00
254.00
Operating Expenses
6.00
6.00
4.00
General and Administration Expenses
-1.00
-1.00
-1.00
Selling and Distribution Expenses
111.00
96.00
91.00
Cost of Software developments
0.00
0.00
0.00
Miscellaneous Expenses
59.00
65.00
48.00
Expenses Capitalised
0.00
0.00
0.00
Total Expenditure
956.00
859.00
756.00
Operating Profit (PBDIT) excl Other Income
239.00
154.00
127.00
Other Income
5.00
6.00
7.00
Operating Profit (PBDIT)
245.00
161.00
135.00
Interest
10.00
14.00
4.00
Profit before Depriciation and Tax
235.00
146.00
130.00
Depreciation
37.00
28.00
20.00
Profit Before Taxation & Exceptional Items
198.00
118.00
110.00
Exceptional Income / Expenses
0.00
0.00
0.00
Profit Before Tax
198.00
118.00
110.00
Provision for Tax
49.00
27.00
25.00
Profit After Tax
149.00
90.00
84.00
Extraordinary Items
0.00
0.00
0.00
Adj to Profit After Tax
0.00
0.00
0.00
Profit Balance B/F
377.00
305.00
228.00
Profit Available for appropriations
527.00
396.00
313.00
Appropriations
527.00
396.00
313.00
Equity Dividend (%)
73.10%
37.00%
27.70%
Earnings Per Share
24.43
14.80
14.57
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2025 is 17.93% vs 14.75% in Mar 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2025 is 55.09% vs 20.90% in Mar 2024

stock-summary

Interest

YoY Growth in year ended Mar 2025 is -26.54% vs 238.26% in Mar 2024

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2025 is 64.70% vs 6.84% in Mar 2024

Compare Profit and Loss Results of Corona Remedies
Markets Mojo
Figures in Cr
consolidated - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
1,196.00
498.00
698.00
140.16%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
1,196.00
498.00
698.00
140.16%
Expenditure (Ex Depriciation)
Stock Adjustments
-23.00
-44.00
21.00
47.73%
Raw Materials Consumed
260.00
214.00
46.00
21.50%
Power & Fuel Cost
6.00
19.00
-13.00
-68.42%
Employee Cost
346.00
28.00
318.00
1,135.71%
Operating Expenses
6.00
22.00
-16.00
-72.73%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
111.00
28.00
83.00
296.43%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
59.00
8.00
51.00
637.50%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
956.00
293.00
663.00
226.28%
Operating Profit (PBDIT) excl Other Income
239.00
205.00
34.00
16.59%
Other Income
5.00
9.00
-4.00
-44.44%
Operating Profit (PBDIT)
245.00
214.00
31.00
14.49%
Interest
10.00
5.00
5.00
100.00%
Profit before Depriciation and Tax
235.00
209.00
26.00
12.44%
Depreciation
37.00
19.00
18.00
94.74%
Profit Before Taxation & Exceptional Items
198.00
189.00
9.00
4.76%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
198.00
184.00
14.00
7.61%
Provision for Tax
49.00
48.00
1.00
2.08%
Profit After Tax
149.00
135.00
14.00
10.37%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
377.00
181.00
196.00
108.29%
Profit Available for appropriations
527.00
320.00
207.00
64.69%
Appropriations
527.00
320.00
207.00
64.69%
Equity Dividend (%)
73.1%
0%
73.10
Earnings Per Share
24.43
1396.27
-1,371.84
-98.25%
Profit And Loss - Net Sales
Net Sales 1,196.41 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 17.93% vs 14.75% in Mar 2024

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 239.97 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 55.09% vs 20.90% in Mar 2024

Profit And Loss - Interest
Interest 10.61 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is -26.54% vs 238.26% in Mar 2024

Profit And Loss - Profit After Tax
Profit After Tax 149.05 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 64.70% vs 6.84% in Mar 2024